- Topics
- Training
Protect your company from cyber risks
Take this self-directed, interactive course to deepen your understanding of cybersecurity risks and learn about the latest regulations to keep your organization compliant and prepared for today’s dangerous cyber environment.
Register Learn more
- Events
Back in person: Compliance Week Europe
Now in its 10th year, Compliance Week Europe is created for compliance, risk, and ethics officers to come together for two days dedicated to the sharing of knowledge and experiences from an international perspective.
REGISTER
- Webcasts
Earn CPE credit with Compliance Week
Compliance Week is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors.
Webcast Library
- Resource Library
- Special Reports
- Membership
Learn from the latest headlines and protect your company today
- DOJ-informed compliance guidance helps Home Depot prep for potential scrutiny
- FTC seeks to expand authority on data breaches, commercial surveillance
- Adtech firm Criteo facing $61M GDPR fine in France
- BIS charges Chinese cable giant with export control violations
Individual Corporate
Close menu
- Home
-
Topics
- Back to parent navigation item
- Topics
- Accounting & Auditing
- AML
- Anti-Bribery
- Anti-Corruption
- Boards & Shareholders
- Cybersecurity
- Data Privacy
- ESG/Social Responsibility
- Ethics & Culture
- Europe
- Financial Services
- GRC Appointments
- Internal Controls
- Regulatory Enforcement
- Regulatory Policy
- Risk Management
- Sanctions
- Surveys & Benchmarking
- Supply Chain
- Technology
- Third Party Risk
- Whistleblowers
- Compensation
- GDPR
- Internal Investigations
- Opinion
- Training
- Culture
- GRC Announcements
- My Compliance Library
- Ask Amii Mailbag
- Nailed It or Failed It
- Risk and Regulatory Compliance
- Accounting and Audit
- Training
- Events
- Webcasts
- Resource Library
- Special Reports
- Membership
The EpiPen controversy’s bad omens for pharmas
By Joe Mont2016-09-27T12:45:00
At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.
THIS IS MEMBERS-ONLY CONTENT
Already a Member? SIGN IN here. If you’re not, click HERE for more information on our 30-day free trials and why you’re not able to view this story.